Aktienanalyse wird geladen …
BIIB · NASDAQ · Biotechnology · USA
226,36 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 9,89 Mrd. | 1,29 Mrd. | 8,79 $ | 147,1 Mio. | 1,3 Mio · 0,9 % | 0,1 Mio · 0,1 % | 75,7 % | 13,1 % | 13,94 $ | 1,98 $ | — |
| 2024 | 9,68 Mrd. | 1,63 Mrd. | 11,18 $ | 145,9 Mio. | 1,3 Mio · 0,9 % | 1 Mio · 0,7 % | 76,1 % | 16,9 % | 18,66 $ | 2,00 $ | — |
| 2023 | 9,84 Mrd. | 1,16 Mrd. | 7,97 $ | 145,6 Mio. | 1,2 Mio · 0,8 % | 1,6 Mio · 1,1 % | 74,2 % | 11,8 % | 8,72 $ | 1,81 $ | — |
| 2022 | 10,17 Mrd. | 3,05 Mrd. | 20,87 $ | 146 Mio. | 1,1 Mio · 0,8 % | 4,7 Mio · 3,2 % | 77,6 % | 30 % | 7,84 $ | 1,74 $ | — |
| 2021 | 10,98 Mrd. | 1,56 Mrd. | 10,40 $ | 149,6 Mio. | 1,1 Mio · 0,7 % | 12,8 Mio · 8,5 % | 80,8 % | 14,2 % | 22,61 $ | 1,59 $ | — |
| 2020 | 13,44 Mrd. | 4 Mrd. | 24,80 $ | 161,3 Mio. | 0,9 Mio · 0,5 % | 27 Mio · 16,7 % | 86,6 % | 29,8 % | 23,59 $ | 1,23 $ | — |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|
| Q1 2026 | 2,48 Mrd. | 319,5 Mio. | 2,15 $ | 148,4 Mio. | 12,9 % | 4,00 $ |
| Q4 2025 | 2,28 Mrd. | -48,9 Mio. | -0,33 $ | 146,7 Mio. | -2,2 % | 3,18 $ |
| Q3 2025 | 2,53 Mrd. | 466,5 Mio. | 3,17 $ | 147,1 Mio. | 18,4 % | 8,34 $ |
| Q2 2025 | 2,65 Mrd. | 634,8 Mio. | 4,33 $ | 146,7 Mio. | 24 % | 0,92 $ |
| Q1 2025 | 2,43 Mrd. | 240,5 Mio. | 1,64 $ | 146,6 Mio. | 9,9 % | 1,52 $ |
| Q4 2024 | 2,45 Mrd. | 266,7 Mio. | 1,81 $ | — | 10,9 % | 4,91 $ |
| Q3 2024 | 2,47 Mrd. | 388,5 Mio. | 2,66 $ | 146,1 Mio. | 15,8 % | 6,16 $ |
| Q2 2024 | 2,46 Mrd. | 583,6 Mio. | 4,00 $ | 145,9 Mio. | 23,7 % | 4,06 $ |
How Investors May Respond To Biogen (BIIB) Advancing At-Home LEQEMBI Pen And Kidney Disease Data
Biogen (BIIB) Posts New Kidney Trial Data, Is It Still 5% Undervalued?
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
Biogen Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for serious neurological, neurodegenerative, and rare diseases. Biogen’s current portfolio includes treatments for multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis, and Friedreich’s ataxia, along with therapies and biosimilars used in specialized immunology and related areas. The company also advances medicines through its research and development programs, with a strong emphasis on neuroscience and immunology. Based in Cambridge, Massachusetts, Biogen serves patients and healthcare providers across multiple global markets through its commercial products and collaborations. Its role in the financial market is shaped by its concentration in specialty biopharmaceuticals, recurring demand for chronic-disease treatments, and continued activity in pipeline development and product commercialization.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest BIIB und jede andere Aktie unbegrenzt.